Galapagos NV (NASDAQ:GLPG) Receives Consensus Recommendation of “Buy” from Analysts
Galapagos NV (NASDAQ:GLPG) has earned an average recommendation of “Buy” from the eight analysts that are presently covering the stock. Three analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is €66.25 ($73.61).
A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Galapagos NV from a “buy” rating to a “hold” rating in a research note on Monday. Credit Suisse Group AG reaffirmed a “hold” rating and set a $48.00 target price on shares of Galapagos NV in a research note on Friday, June 17th. Finally, Janney Montgomery Scott assumed coverage on shares of Galapagos NV in a research note on Tuesday, August 30th. They set a “buy” rating and a $64.00 target price on the stock.
Shares of Galapagos NV (NASDAQ:GLPG) traded down 1.29% during midday trading on Tuesday, hitting $64.16. 34,639 shares of the stock traded hands. The company’s market cap is $2.96 billion. The stock has a 50-day moving average of $58.65 and a 200-day moving average of $52.67. Galapagos NV has a 52-week low of $37.03 and a 52-week high of $73.37.
Large investors have recently made changes to their positions in the stock. Fiera Capital Corp bought a new stake in shares of Galapagos NV during the second quarter worth $302,000. Citadel Advisors LLC acquired a new position in shares of Galapagos NV during the second quarter worth $347,000. Landscape Capital Management L.L.C. boosted its position in shares of Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock worth $727,000 after buying an additional 9,288 shares during the period. A.R.T. Advisors LLC acquired a new position in shares of Galapagos NV during the first quarter worth $547,000. Finally, P.A.W. Capital Corp acquired a new position in shares of Galapagos NV during the second quarter worth $1,109,000.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.